Securities class action litigation has been filed on behalf of investors who purchased or otherwise acquired the common stock of Dentsply Sirona Inc. (“Dentsply” or the “Company”) between December 1, 2022 and November 6, 2024, inclusive (the “Class Period”).

If you purchased or otherwise acquired Dentsply common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than January 27, 2025.

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Dentsply investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should complete the form below, text or email investorinfo@lchb.com, or call Lieff Cabraser  partner Sharon M. Lee at 1-800-541-7358.

Dentsply, incorporated in Delaware and headquartered in Charlotte, North Carolina, manufactures professional dental products, including Byte, an affordable, “doctor-directed,” direct-to-consumer dental aligner.

The action alleges that Dentsply made materially false and misleading statements throughout the Class Period, and failed to disclose material adverse facts about its business, operations, and prospects, including that: (1) the Company targeted their Byte sales towards low-income individuals who lacked access to quality dental care, and were therefore more likely to have underlying dental issues making them ineligible for the treatment; (2) the drive for Byte growth and sales commissions led employees to sell to contraindicated patients; (3) Dentsply’s process for onboarding Byte patients failed to provide adequate assurance that contraindicated patients would not be treated; (4) the Company knew its Byte products were severely injuring patients, but failed to adequately investigate instances of those injuries; (5) Dentsply lacked systems to notify the FDA of such injuries within 30 days of learning of them, as required; and (6) the Company materially overstated the goodwill value of their Byte business.

On October 24, 2024, Dentsply announced the “voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products.” Dentsply initially claimed that this was simply a “precautionary measure”; however, the next day, Dentsply CEO, defendant Simon D. Campion, revealed that discussions with the FDA had led to the suspension over concerns that the Company’s patient onboarding process failed to adequately screen contraindicated patients from treatment with Byte aligners. Dentsply also disclosed that it expected to record a goodwill impairment charge of between $450 million and $550 million. On this news, the price of Dentsply common stock fell $1.10 per share, or 4.5%, from a closing price of $24.41 on October 24, 2024, to close at $23.31 per share on October 25, 2024, on heavy trading volume.

On November 7, 2024, Dentsply announced a goodwill impairment charge of $495 million and lowered its financial forecast for 2024, including reduced adjusted earnings per share of $1.82 to $1.86 (previously $1.96 to $2.02). In the corresponding earnings call, CEO Campion stated that the Company was considering the discontinuation of some or all of its Byte business. On this news, the price of Dentsply common stock fell $6.72 per share, or 28.02%, from a closing price of $23.98 per share on November 6, 2024, to close at $17.26 per share on November 7, 2024, on extremely heavy trading volume.

Read our Securities and Investment Fraud Practice Area brochure